clomipramine has been researched along with Panic Disorder in 56 studies
Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.
clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.
Panic Disorder: A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Blunted neuroendocrine and physiological responses to the selective 5-HT(1A) receptor agonist, ipsapirone, have been observed in patients with panic disorder and/or agoraphobia (PDA)." | 9.10 | 5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo. ( Bandelow, B; Bartmann, U; Broocks, A; George, A; Hillmer-Vogel, U; Meyer, T; Opitz, M; Pekrun, G; Rüther, E; Wedekind, D, 2003) |
| "This study was designed to explore the dose-response relationship for clomipramine in patients with panic disorder, with or without agoraphobia." | 9.09 | Comparative effects of low and high doses of clomipramine and placebo in panic disorder: a double-blind controlled study. French University Antidepressant Group. ( Caillard, V; Markabi, S; Rouillon, F; Viel, JF, 1999) |
| "Eighty-one panic disorder patients with or without agoraphobia were treated with flexible doses of clomipramine under single-blind conditions." | 9.09 | A dose-finding and discontinuation study of clomipramine in panic disorder. ( Andrade, L; Bernik, M; Cordas, T; Gentil, V; Gorenstein, C; Lotufo-Neto, F; Melo, M; Ramos, RT, 2001) |
| "To examine the effects of long-term treatment with citalopram or clomipramine on subjective phobic symptoms in patients with panic disorder." | 9.09 | Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. ( Koponen, H; Lehto, H; Leinonen, E; Lepola, U; Turtonen, J; Wade, A, 2000) |
| "This 12-week, placebo-controlled study was carried out to compare the relative efficacy of paroxetine, clomipramine, and cognitive therapy in the treatment of DSM-III-R-defined panic disorder with or without agoraphobia." | 9.09 | Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. ( Bakker, A; Spinhoven, P; van Balkom, AJ; van Dyck, R, 1999) |
| "The primary objectives of this multicenter study were to determine the efficacy and safety of moclobemide, a selective reversible inhibitor of monoamino oxidase A, as drug treatment in DSM-III-R panic disorder with and without agoraphobia." | 9.09 | The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. ( Dahl, AA; Krüger, MB, 1999) |
| "Several placebo-controlled trials have shown the efficacy of clomipramine (CMI) in panic disorder." | 9.09 | Serum levels of clomipramine and desmethylclomipramine and clinical improvement in panic disorder. ( da Motta Singer, J; Gorenstein, C; Marcourakis, T; Ramos, RT, 1999) |
| "To compare the efficacy of clomipramine hydrochloride (CMI), a serotonin reuptake inhibitor with the noradrenergic tricyclic antidepressant agent, and desipramine hydrochloride (DMI) for patients with panic disorder (PD)." | 9.09 | A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. ( Dannon, PN; Fux, M; Iancu, I; Sasson, Y; Taub, M; Zohar, J, 1999) |
| "These results suggest that regular aerobic exercise alone, in comparison with placebo, is associated with significant clinical improvement in patients suffering from panic disorder, but that it is less effective than treatment with clomipramine." | 9.08 | Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. ( Bandelow, B; Bartmann, U; Broocks, A; George, A; Hillmer-Vogel, U; Meyer, T; Pekrun, G; Rüther, E, 1998) |
| "Fifty-eight patients with DSM-III-R panic disorder with or without agoraphobia underwent 13 weeks of clomipramine treatment." | 9.08 | Clomipramine treatment of panic disorder: pros and cons. ( Campeas, R; Coplan, JD; Fallon, BA; Fyer, AJ; Gorman, JM; Klein, DF; Leibowitz, MR; Papp, LA; Schneier, FR, 1997) |
| "Treatment with citalopram at 20 or 30 mg, 40 or 60 mg and clomipramine were significantly superior to placebo, judged by the number of patients free of panic attacks in the week prior to the final assessment." | 9.08 | The effect of citalopram in panic disorder. ( Koponen, HJ; Lepola, U; Pedersen, T; Pedersen, V; Wade, AG, 1997) |
| "The aim of this 12-week, double-blind, parallel group, placebo-controlled study was to compare paroxetine with clomipramine in 367 patients with DSM-III-R defined panic disorder." | 9.08 | A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. ( Bakker, A; Dunbar, G; Judge, R; Lecrubier, Y, 1997) |
| "We examined the effects of long-term (six months) treatment with the serotonin potentiating tricyclic antidepressant clomipramine on several serotonergic parameters in panic disorder and depressive patients." | 9.08 | Effects of clomipramine on plasma amino acids and serotonergic parameters in panic disorder and depression. ( Fekkes, D; Pepplinkhuizen, L; Timmerman, L, 1997) |
| "Paroxetine has been shown to be effective in panic disorder in three 10- to 12-week studies." | 9.08 | Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. ( Judge, R; Lecrubier, Y, 1997) |
| "Among 79 volunteer, unpaid, family doctor-referred psychiatric out patients with DSM III-R panic disorder, with and without agoraphobia, 66 completed a six week placebo-controlled trial of lofepramine versus clomipramine and 57 survivors were followed up for 6 months." | 9.07 | The Galway Study of Panic Disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial. ( Brophy, J; Fahy, TJ; O'Rourke, D; Schazmann, W; Sciascia, S, 1992) |
| "A double-blind, placebo-controlled trial was undertaken to compare the effects of imipramine and clomipramine in the treatment of panic disorder with or without agoraphobia." | 9.07 | Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. ( Eriksson, E; Modigh, K; Westberg, P, 1992) |
| "This study investigated the chronic use (6." | 5.31 | Memory performance in panic disorder patients after chronic use of clomipramine. ( Artes, R; de Carvalho, SC; Gorenstein, C; Marcourakis, T, 2002) |
| "They failed clomipramine hydrochloride treatment as the panic attacks resumed, occasionally even with greater frequency." | 5.29 | [The clinico-psychopathological characteristics of patients with panic disorders and the efficacy of clomipramine therapy]. ( Kalinin, VV; Maksimova, MA, 1993) |
| "The differential effectiveness of cognitive therapy and antidepressant treatment (paroxetine or clomipramine) was investigated in a sample of 129 panic disorder patients in a 12-week, pretest posttest placebo-controlled study." | 5.12 | Which panic disorder patients benefit from which treatment: cognitive therapy or antidepressants? ( Bakker, A; Dusseldorp, E; Spinhoven, P; van Balkom, AJ; van Dyck, R, 2007) |
| "In this study, 12 fully remitted panic disorder patients, complaining of severe clomipramine-induced ejaculatory delay, were randomly assigned to either bethanecol chloride tablets (20 mg, as needed) or placebo in a randomized, double-blind, placebo-controlled, two-period crossover study." | 5.11 | Bethanecol chloride for treatment of clomipramine-induced orgasmic dysfunction in males. ( Bernik, M; Nunes, PV; Vieira, AH, 2004) |
| "Blunted neuroendocrine and physiological responses to the selective 5-HT(1A) receptor agonist, ipsapirone, have been observed in patients with panic disorder and/or agoraphobia (PDA)." | 5.10 | 5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo. ( Bandelow, B; Bartmann, U; Broocks, A; George, A; Hillmer-Vogel, U; Meyer, T; Opitz, M; Pekrun, G; Rüther, E; Wedekind, D, 2003) |
| "Several placebo-controlled trials have shown the efficacy of clomipramine (CMI) in panic disorder." | 5.09 | Serum levels of clomipramine and desmethylclomipramine and clinical improvement in panic disorder. ( da Motta Singer, J; Gorenstein, C; Marcourakis, T; Ramos, RT, 1999) |
| "The primary objectives of this multicenter study were to determine the efficacy and safety of moclobemide, a selective reversible inhibitor of monoamino oxidase A, as drug treatment in DSM-III-R panic disorder with and without agoraphobia." | 5.09 | The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. ( Dahl, AA; Krüger, MB, 1999) |
| "This study was designed to explore the dose-response relationship for clomipramine in patients with panic disorder, with or without agoraphobia." | 5.09 | Comparative effects of low and high doses of clomipramine and placebo in panic disorder: a double-blind controlled study. French University Antidepressant Group. ( Caillard, V; Markabi, S; Rouillon, F; Viel, JF, 1999) |
| "Ninety-five panic disorder patients, randomized to receive double-blind treatment with paroxetine, clomipramine or placebo for twelve weeks, were asked half-way through this period to classify treatment as active or placebo." | 5.09 | Double-blindness procedure did not mask giving of medication in panic disorder. ( Bakker, A; Matser, D; Spinhoven, P; van Balkom, AJ; van Dyck, R, 1999) |
| "This 12-week, placebo-controlled study was carried out to compare the relative efficacy of paroxetine, clomipramine, and cognitive therapy in the treatment of DSM-III-R-defined panic disorder with or without agoraphobia." | 5.09 | Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. ( Bakker, A; Spinhoven, P; van Balkom, AJ; van Dyck, R, 1999) |
| "To examine the effects of long-term treatment with citalopram or clomipramine on subjective phobic symptoms in patients with panic disorder." | 5.09 | Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. ( Koponen, H; Lehto, H; Leinonen, E; Lepola, U; Turtonen, J; Wade, A, 2000) |
| "Patients with Panic disorder (DSM-IV) were randomly assigned to three treatment modalities: running (n=45), clomipramine (n=15) or placebo (n=15)." | 5.09 | The use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial. ( Bandelow, B; Bartmann, U; Broocks, A; George, A; Hillmer-Vogel, U; Meyer, T; Pekrun, G; Pralle, L; Rüther, E, 2000) |
| "Eighty-one panic disorder patients with or without agoraphobia were treated with flexible doses of clomipramine under single-blind conditions." | 5.09 | A dose-finding and discontinuation study of clomipramine in panic disorder. ( Andrade, L; Bernik, M; Cordas, T; Gentil, V; Gorenstein, C; Lotufo-Neto, F; Melo, M; Ramos, RT, 2001) |
| "To compare the efficacy of clomipramine hydrochloride (CMI), a serotonin reuptake inhibitor with the noradrenergic tricyclic antidepressant agent, and desipramine hydrochloride (DMI) for patients with panic disorder (PD)." | 5.09 | A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. ( Dannon, PN; Fux, M; Iancu, I; Sasson, Y; Taub, M; Zohar, J, 1999) |
| "Paroxetine has been shown to be effective in panic disorder in three 10- to 12-week studies." | 5.08 | Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. ( Judge, R; Lecrubier, Y, 1997) |
| "The aim of this 12-week, double-blind, parallel group, placebo-controlled study was to compare paroxetine with clomipramine in 367 patients with DSM-III-R defined panic disorder." | 5.08 | A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. ( Bakker, A; Dunbar, G; Judge, R; Lecrubier, Y, 1997) |
| "Fifty-eight patients with DSM-III-R panic disorder with or without agoraphobia underwent 13 weeks of clomipramine treatment." | 5.08 | Clomipramine treatment of panic disorder: pros and cons. ( Campeas, R; Coplan, JD; Fallon, BA; Fyer, AJ; Gorman, JM; Klein, DF; Leibowitz, MR; Papp, LA; Schneier, FR, 1997) |
| "The addition of brief dynamic psychotherapy to treatment with clomipramine significantly reduces the relapse rate of panic disorder compared with clomipramine treatment alone." | 5.08 | Does brief dynamic psychotherapy reduce the relapse rate of panic disorder? ( Dahl, AA; Wiborg, IM, 1996) |
| "Forty-seven patients meeting DSM-III-R criteria for panic disorder with agoraphobia (PAG) were assessed by the Minnesota Multiphasic Personality Inventory (MMPI) at baseline and after 8 weeks of treatment with imipramine, clomipramine and placebo." | 5.08 | Minnesota Multiphasic Personality Inventory correlates of panic disorder with agoraphobia: changes with treatment. ( Gentil, V; Gorenstein, C; Ito, LM; Miyakawa, E, 1995) |
| "Endurance capacity was determined by bicycle spiroergometry in patients with panic disorder before (n = 38) and after (n = 10) a 10 week running program and compared to untrained healthy control subjects carrying out the same training (n = 11) and patients receiving clomipramine drug therapy (n = 7) or placebo (n = 7)." | 5.08 | Endurance training in panic patients: spiroergometric and clinical effects. ( Bandelow, B; Broocks, A; Hillmer-Vogel, U; Meyer, T; Rüther, E, 1998) |
| "These results suggest that regular aerobic exercise alone, in comparison with placebo, is associated with significant clinical improvement in patients suffering from panic disorder, but that it is less effective than treatment with clomipramine." | 5.08 | Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. ( Bandelow, B; Bartmann, U; Broocks, A; George, A; Hillmer-Vogel, U; Meyer, T; Pekrun, G; Rüther, E, 1998) |
| "Treatment with citalopram at 20 or 30 mg, 40 or 60 mg and clomipramine were significantly superior to placebo, judged by the number of patients free of panic attacks in the week prior to the final assessment." | 5.08 | The effect of citalopram in panic disorder. ( Koponen, HJ; Lepola, U; Pedersen, T; Pedersen, V; Wade, AG, 1997) |
| "We examined the effects of long-term (six months) treatment with the serotonin potentiating tricyclic antidepressant clomipramine on several serotonergic parameters in panic disorder and depressive patients." | 5.08 | Effects of clomipramine on plasma amino acids and serotonergic parameters in panic disorder and depression. ( Fekkes, D; Pepplinkhuizen, L; Timmerman, L, 1997) |
| " This paper reports a randomized, double-blind, 8-week trial in which the efficacy and safety of brofaromine was compared to clomipramine in patients with panic disorder with or without agoraphobia." | 5.07 | Reversible monoamine oxidase-A inhibitors in panic disorder. ( Bakish, D; Bowen, R; D'Souza, J; Saxena, BM, 1993) |
| "Sixty six patients with panic disorders, fulfilling the DSM III criteria for panic attack, together with a group of age and sex matched controls, were studied for changes in their peripheral noradrenergic and serotonergic status before treatment and during six months treatment with either clomipramine or lofepramine." | 5.07 | The Galway Study of Panic Disorder. II: Changes in some peripheral markers of noradrenergic and serotonergic function in DSM III-R panic disorder. ( Butler, J; Leonard, BE; O'Halloran, A, 1992) |
| "A double-blind, placebo-controlled trial was undertaken to compare the effects of imipramine and clomipramine in the treatment of panic disorder with or without agoraphobia." | 5.07 | Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. ( Eriksson, E; Modigh, K; Westberg, P, 1992) |
| "A double-blind 12 week trial was undertaken to compare the effects of clomipramine + dixyrazine with clomipramine + placebo in the treatment of panic disorder with or without agoraphobia." | 5.07 | Increased antipanic efficacy in combined treatment with clomipramine and dixyrazine. ( Feet, PO; Götestam, KG, 1994) |
| "Among 79 volunteer, unpaid, family doctor-referred psychiatric out patients with DSM III-R panic disorder, with and without agoraphobia, 66 completed a six week placebo-controlled trial of lofepramine versus clomipramine and 57 survivors were followed up for 6 months." | 5.07 | The Galway Study of Panic Disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial. ( Brophy, J; Fahy, TJ; O'Rourke, D; Schazmann, W; Sciascia, S, 1992) |
| "Eighteen patients with panic disorder with agoraphobia who had not responded to previous inpatient behavioral treatment were recruited to a 12-week, placebo-controlled, double-blind crossover study of clomipramine, at top doses of 150 mg/day for 3 weeks." | 5.07 | Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy. ( Bille, H; Due-Madsen, J; Gude, T; Hoffart, A; Lande, B; Torgersen, S, 1993) |
| "(1) Citalopram, a serotonin reuptake inhibitor antidepressant, now has a new licensed indication, in the preventive treatment of panic attacks." | 3.70 | Citalopram: new indication. No advantage. ( , 1999) |
| "Painful ejaculation following the administration of imipramine and clomipramine is described in four patients." | 3.68 | Painful ejaculation associated with antidepressants in four patients. ( Aizenberg, D; Hermesh, H; Karp, L; Weizman, A; Zemishlany, Z, 1991) |
| "Panic disorder is common in the general population with a prevalence of 1% to 4%." | 3.01 | Pharmacological treatments in panic disorder in adults: a network meta-analysis. ( Barbui, C; Bighelli, I; Caldwell, DM; Cipriani, A; Davies, SJ; Dawson, S; Dias, S; Furukawa, TA; Guaiana, G; Imai, H; Koesters, M; Meader, N; Pompoli, A; Robertson, L; Tajika, A, 2023) |
| "Panic disorder is a chronic and recurring condition, and there is therefore a need for long-term therapy." | 2.40 | The long-term treatment of panic disorder. ( Davidson, JR, 1998) |
| "This study investigated the chronic use (6." | 1.31 | Memory performance in panic disorder patients after chronic use of clomipramine. ( Artes, R; de Carvalho, SC; Gorenstein, C; Marcourakis, T, 2002) |
| "Patients with Tourette's syndrome often develop multiple psychopathological symptoms beyond the basic symptoms (motor and vocal tics)." | 1.31 | [Disguised Tourette's syndrome. A contribution to the differential diagnosis on phobia and fear]. ( Barnett, W; Bednarz, K; Haisch, S, 2002) |
| "Sertraline has been tested extensively in the treatment of panic and obsessive-compulsive disorders." | 1.31 | Sertraline in the treatment of anxiety disorders. ( Hirschfeld, RM, 2000) |
| " No threshold changes were observed following the long-term administration of the higher dose of either CLM or FLX." | 1.31 | Long-term effects of clomipramine and fluoxetine on dorsal periaqueductal grey-evoked innate defensive behaviours of the rat. ( Schenberg, LC; Vargas, LC, 2001) |
| "They failed clomipramine hydrochloride treatment as the panic attacks resumed, occasionally even with greater frequency." | 1.29 | [The clinico-psychopathological characteristics of patients with panic disorders and the efficacy of clomipramine therapy]. ( Kalinin, VV; Maksimova, MA, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 39 (69.64) | 18.2507 |
| 2000's | 15 (26.79) | 29.6817 |
| 2010's | 1 (1.79) | 24.3611 |
| 2020's | 1 (1.79) | 2.80 |
| Authors | Studies |
|---|---|
| Guaiana, G | 1 |
| Meader, N | 1 |
| Barbui, C | 1 |
| Davies, SJ | 1 |
| Furukawa, TA | 1 |
| Imai, H | 1 |
| Dias, S | 1 |
| Caldwell, DM | 1 |
| Koesters, M | 1 |
| Tajika, A | 1 |
| Bighelli, I | 1 |
| Pompoli, A | 1 |
| Cipriani, A | 1 |
| Dawson, S | 1 |
| Robertson, L | 1 |
| Marazziti, D | 1 |
| Carlini, M | 1 |
| Dell'Osso, L | 1 |
| Bernik, MA | 1 |
| Corregiari, FM | 1 |
| Braun, IM | 1 |
| Bednarz, K | 1 |
| Haisch, S | 1 |
| Barnett, W | 1 |
| de Carvalho, SC | 1 |
| Marcourakis, T | 2 |
| Artes, R | 1 |
| Gorenstein, C | 4 |
| Broocks, A | 4 |
| Meyer, T | 4 |
| Opitz, M | 1 |
| Bartmann, U | 3 |
| Hillmer-Vogel, U | 4 |
| George, A | 3 |
| Pekrun, G | 3 |
| Wedekind, D | 1 |
| Rüther, E | 4 |
| Bandelow, B | 4 |
| Murai, T | 1 |
| Takagi, S | 1 |
| Bernik, M | 2 |
| Vieira, AH | 1 |
| Nunes, PV | 1 |
| Garcia-Leal, C | 1 |
| Parente, AC | 1 |
| Del-Ben, CM | 1 |
| Guimarães, FS | 1 |
| Moreira, AC | 1 |
| Elias, LL | 1 |
| Graeff, FG | 1 |
| Fontenelle, LF | 1 |
| Mendlowicz, MV | 1 |
| Kalaf, J | 1 |
| Domingues, AM | 1 |
| Versiani, M | 1 |
| Dusseldorp, E | 1 |
| Spinhoven, P | 3 |
| Bakker, A | 4 |
| van Dyck, R | 3 |
| van Balkom, AJ | 3 |
| George, DT | 1 |
| Nutt, DJ | 2 |
| Rawlings, RR | 1 |
| Phillips, MJ | 1 |
| Eckardt, MJ | 1 |
| Potter, WZ | 1 |
| Linnoila, M | 1 |
| Feet, PO | 1 |
| Götestam, KG | 1 |
| Nofzinger, EA | 1 |
| Reynolds, CF | 1 |
| Kalinin, VV | 1 |
| Maksimova, MA | 1 |
| Hoffart, A | 1 |
| Due-Madsen, J | 1 |
| Lande, B | 1 |
| Gude, T | 1 |
| Bille, H | 1 |
| Torgersen, S | 1 |
| Bakish, D | 1 |
| Saxena, BM | 1 |
| Bowen, R | 1 |
| D'Souza, J | 1 |
| Pols, H | 1 |
| Lousberg, H | 1 |
| Zandbergen, J | 1 |
| Griez, E | 1 |
| Vila, G | 1 |
| Mouren-Simeoni, MC | 1 |
| Ito, LM | 1 |
| Gentil, V | 2 |
| Miyakawa, E | 1 |
| Wiborg, IM | 1 |
| Dahl, AA | 2 |
| O'Rourke, D | 2 |
| Fahy, TJ | 2 |
| Prescott, P | 1 |
| Sheehan, DV | 1 |
| Harnett-Sheehan, K | 1 |
| Lecrubier, Y | 2 |
| Dunbar, G | 1 |
| Judge, R | 2 |
| Perna, G | 1 |
| Bertani, A | 1 |
| Gabriele, A | 1 |
| Politi, E | 1 |
| Bellodi, L | 1 |
| Fekkes, D | 1 |
| Timmerman, L | 1 |
| Pepplinkhuizen, L | 1 |
| Wade, AG | 1 |
| Lepola, U | 2 |
| Koponen, HJ | 1 |
| Pedersen, V | 1 |
| Pedersen, T | 1 |
| Papp, LA | 1 |
| Schneier, FR | 1 |
| Fyer, AJ | 1 |
| Leibowitz, MR | 1 |
| Gorman, JM | 1 |
| Coplan, JD | 1 |
| Campeas, R | 1 |
| Fallon, BA | 1 |
| Klein, DF | 1 |
| Stein, MB | 1 |
| Davidson, JR | 1 |
| Caillard, V | 1 |
| Rouillon, F | 1 |
| Viel, JF | 1 |
| Markabi, S | 1 |
| Benazzi, F | 1 |
| Sasson, Y | 1 |
| Iancu, I | 1 |
| Fux, M | 1 |
| Taub, M | 1 |
| Dannon, PN | 1 |
| Zohar, J | 1 |
| van der Feltz-Cornelis, CM | 1 |
| Ramos, RT | 2 |
| da Motta Singer, J | 1 |
| Krüger, MB | 1 |
| Matser, D | 1 |
| Leinonen, E | 1 |
| Koponen, H | 1 |
| Turtonen, J | 1 |
| Wade, A | 1 |
| Lehto, H | 1 |
| Hirschfeld, RM | 1 |
| Toni, C | 1 |
| Perugi, G | 1 |
| Frare, F | 1 |
| Mata, B | 1 |
| Vitale, B | 1 |
| Mengali, F | 1 |
| Recchia, M | 1 |
| Serra, G | 1 |
| Akiskal, HS | 1 |
| Pralle, L | 1 |
| Lotufo-Neto, F | 1 |
| Andrade, L | 1 |
| Cordas, T | 1 |
| Melo, M | 1 |
| Vargas, LC | 1 |
| Schenberg, LC | 1 |
| Kaplan, R | 1 |
| Butler, J | 1 |
| O'Halloran, A | 1 |
| Leonard, BE | 1 |
| Modigh, K | 2 |
| Westberg, P | 2 |
| Eriksson, E | 2 |
| Brophy, J | 1 |
| Schazmann, W | 1 |
| Sciascia, S | 1 |
| Aizenberg, D | 1 |
| Zemishlany, Z | 1 |
| Hermesh, H | 1 |
| Karp, L | 1 |
| Weizman, A | 1 |
| Vazquez Rodriguez, AM | 1 |
| Arranz Peña, MI | 1 |
| Lopez Ibor, JJ | 1 |
| Garcia Aguilera, M | 1 |
| Viñas, R | 1 |
| Moreno, I | 1 |
| Vecino Morales, AM | 1 |
| Lisjö, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Controlled Trial on the Effects of Paroxetine Versus Placebo in Combination With Aerobic Exercise or Relaxation Training in the Treatment of Panic Disorder[NCT00540098] | Phase 4 | 75 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for clomipramine and Panic Disorder
| Article | Year |
|---|---|
Pharmacological treatments in panic disorder in adults: a network meta-analysis.
Topics: Adult; Alprazolam; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzodiazepines; Clomipr | 2023 |
Treatment strategies of obsessive-compulsive disorder and panic disorder/agoraphobia.
Topics: Agoraphobia; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Clomipramine; Cognit | 2012 |
The role of SSRIs in panic disorder.
Topics: 1-Naphthylamine; Citalopram; Clinical Trials as Topic; Clomipramine; Fluoxetine; Fluvoxamine; Humans | 1996 |
Medication treatments for panic disorder and social phobia.
Topics: Antidepressive Agents, Tricyclic; Benzamides; Benzodiazepines; Citalopram; Clinical Trials as Topic; | 1998 |
Antidepressants in panic disorder: clinical and preclinical mechanisms.
Topics: Antidepressive Agents; Clomipramine; Fluoxetine; Humans; Panic Disorder; Raphe Nuclei; Receptors, Se | 1998 |
The long-term treatment of panic disorder.
Topics: Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Clomipramine; Cognitive Behavioral Thera | 1998 |
32 trials available for clomipramine and Panic Disorder
| Article | Year |
|---|---|
5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo.
Topics: Adolescent; Adult; Agoraphobia; Body Temperature; Clomipramine; Combined Modality Therapy; Double-Bl | 2003 |
Bethanecol chloride for treatment of clomipramine-induced orgasmic dysfunction in males.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Bethanechol; Clomipramine; Cross-Over Stu | 2004 |
Which panic disorder patients benefit from which treatment: cognitive therapy or antidepressants?
Topics: Adolescent; Adult; Antidepressive Agents; Clomipramine; Cognitive Behavioral Therapy; Female; Humans | 2007 |
Behavioral and endocrine responses to clomipramine in panic disorder patients with or without alcoholism.
Topics: Adrenocorticotropic Hormone; Adult; Alcoholism; Arousal; Brain; Clomipramine; Female; Humans; Hydroc | 1995 |
Increased antipanic efficacy in combined treatment with clomipramine and dixyrazine.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clomipramine; Double-Blind Method; Drug Therapy, Combi | 1994 |
Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy.
Topics: Adult; Agoraphobia; Behavior Therapy; Clomipramine; Combined Modality Therapy; Double-Blind Method; | 1993 |
Reversible monoamine oxidase-A inhibitors in panic disorder.
Topics: Agoraphobia; Clomipramine; Double-Blind Method; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibit | 1993 |
Minnesota Multiphasic Personality Inventory correlates of panic disorder with agoraphobia: changes with treatment.
Topics: Adolescent; Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Clomipramine; Female; Humans; Imip | 1995 |
Does brief dynamic psychotherapy reduce the relapse rate of panic disorder?
Topics: Clomipramine; Combined Modality Therapy; Humans; Panic Disorder; Psychiatric Status Rating Scales; P | 1996 |
The Galway Study of Panic Disorder. IV. Temporal stability of diagnosis by present state examination test-retest.
Topics: Antidepressive Agents, Tricyclic; Clomipramine; Double-Blind Method; Follow-Up Studies; Humans; Lofe | 1996 |
A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators.
Topics: Adolescent; Adult; Aged; Clomipramine; Double-Blind Method; Female; Humans; Male; Middle Aged; Panic | 1997 |
Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators.
Topics: Adolescent; Adult; Aged; Clomipramine; Double-Blind Method; Female; Humans; Long-Term Care; Male; Mi | 1997 |
Modification of 35% carbon dioxide hypersensitivity across one week of treatment with clomipramine and fluvoxamine: a double-blind, randomized, placebo-controlled study.
Topics: Adult; Carbon Dioxide; Clomipramine; Cross-Over Studies; Double-Blind Method; Female; Fluvoxamine; H | 1997 |
Effects of clomipramine on plasma amino acids and serotonergic parameters in panic disorder and depression.
Topics: Adult; Amino Acids; Antidepressive Agents, Tricyclic; Blood Platelets; Clomipramine; Depressive Diso | 1997 |
The effect of citalopram in panic disorder.
Topics: Adolescent; Adult; Aged; Citalopram; Clomipramine; Dose-Response Relationship, Drug; Double-Blind Me | 1997 |
Clomipramine treatment of panic disorder: pros and cons.
Topics: Adult; Aged; Agoraphobia; Antidepressive Agents, Tricyclic; Clomipramine; Comorbidity; Drug Administ | 1997 |
Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder.
Topics: Adult; Agoraphobia; Bias; Clomipramine; Comorbidity; Exercise; Female; Humans; Male; Outcome Assessm | 1998 |
Endurance training in panic patients: spiroergometric and clinical effects.
Topics: Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Clomipramine; Exercise Therapy; Female; Humans | 1998 |
Comparative effects of low and high doses of clomipramine and placebo in panic disorder: a double-blind controlled study. French University Antidepressant Group.
Topics: Adolescent; Adult; Aged; Clomipramine; Dose-Response Relationship, Drug; Double-Blind Method; Female | 1999 |
A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder.
Topics: Adult; Antidepressive Agents, Tricyclic; Clomipramine; Cross-Over Studies; Desipramine; Double-Blind | 1999 |
Serum levels of clomipramine and desmethylclomipramine and clinical improvement in panic disorder.
Topics: Adult; Antidepressive Agents, Tricyclic; Clomipramine; Female; Humans; Male; Middle Aged; Panic Diso | 1999 |
The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder.
Topics: Adult; Aged; Benzamides; Chi-Square Distribution; Chronic Disease; Clomipramine; Female; Humans; Mal | 1999 |
Double-blindness procedure did not mask giving of medication in panic disorder.
Topics: Clomipramine; Double-Blind Method; Humans; Panic Disorder; Paroxetine; Psychiatric Status Rating Sca | 1999 |
Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder.
Topics: Adolescent; Adult; Aged; Agoraphobia; Clomipramine; Cognitive Behavioral Therapy; Comorbidity; Doubl | 1999 |
Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial.
Topics: Adolescent; Adult; Aged; Citalopram; Clomipramine; Dose-Response Relationship, Drug; Female; Humans; | 2000 |
A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants.
Topics: Adult; Aged; Agoraphobia; Antidepressive Agents; Clomipramine; Demography; Female; Humans; Imipramin | 2000 |
The use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial.
Topics: Agoraphobia; Antidepressive Agents, Tricyclic; Clomipramine; Combined Modality Therapy; Double-Blind | 2000 |
A dose-finding and discontinuation study of clomipramine in panic disorder.
Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Clomipramine; Dose-Response Relationship, Drug; | 2001 |
The Galway Study of Panic Disorder. II: Changes in some peripheral markers of noradrenergic and serotonergic function in DSM III-R panic disorder.
Topics: Adult; Blood Platelets; Clomipramine; Double-Blind Method; Female; Humans; Lymphocytes; Male; Norepi | 1992 |
Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial.
Topics: Adult; Clomipramine; Diazepam; Double-Blind Method; Female; Humans; Imipramine; Male; Panic Disorder | 1992 |
The Galway Study of Panic Disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial.
Topics: Adult; Agoraphobia; Behavior Therapy; Clomipramine; Combined Modality Therapy; Female; Humans; Lofep | 1992 |
Clomipramine test: serum level determination in three groups of psychiatric patients.
Topics: Adolescent; Adult; Clomipramine; Female; Gambling; Humans; Male; Middle Aged; Obsessive-Compulsive D | 1991 |
18 other studies available for clomipramine and Panic Disorder
| Article | Year |
|---|---|
Panic attacks in the differential diagnosis and treatment of resistant epilepsy.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Tricyclic; Clomipramine; Clonazepam; Diagnosis, Diffe | 2002 |
[Disguised Tourette's syndrome. A contribution to the differential diagnosis on phobia and fear].
Topics: Adult; Anxiety Disorders; Clomipramine; Clonazepam; Cognitive Behavioral Therapy; Combined Modality | 2002 |
Memory performance in panic disorder patients after chronic use of clomipramine.
Topics: Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Chronic Disease; Clomipramine; Female; Humans; | 2002 |
Charles Bonnet syndrome and panic disorder.
Topics: Adult; Antidepressive Agents, Tricyclic; Clomipramine; Hallucinations; Humans; Male; Panic Disorder; | 2004 |
Anxiety and salivary cortisol in symptomatic and nonsymptomatic panic patients and healthy volunteers performing simulated public speaking.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety; Circadian Rhythm; Clomipramine; Female; Healthy Vo | 2005 |
Obsessions with aggressive content emerging during the course of panic disorder: a different subtype of obsessive-compulsive disorder?
Topics: Adult; Aggression; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Benzodiazepines; Clomipram | 2005 |
REM sleep behavior disorder.
Topics: Adult; Clomipramine; Female; Humans; Obsessive-Compulsive Disorder; Panic Disorder; Sleep Wake Disor | 1994 |
[The clinico-psychopathological characteristics of patients with panic disorders and the efficacy of clomipramine therapy].
Topics: Adult; Chronic Disease; Clomipramine; Drug Evaluation; Female; Humans; Male; Middle Aged; Panic Diso | 1993 |
Panic disorder patients show decrease in ventilatory response to CO2 after clomipramine treatment.
Topics: Adult; Carbon Dioxide; Clomipramine; Female; Humans; Male; Middle Aged; Panic Disorder; Respiration; | 1993 |
[Panic attacks and panic disorders in the child].
Topics: Anxiety, Separation; Child; Clomipramine; Depressive Disorder; Dose-Response Relationship, Drug; Dru | 1993 |
Fluoxetine for clomipramine withdrawal symptoms.
Topics: Adult; Clomipramine; Comorbidity; Depressive Disorder; Fluoxetine; Humans; Male; Panic Disorder; Sub | 1999 |
[Hot flashes resistant to hormone replacement in menopausal women: panic disorder?].
Topics: Behavior Therapy; Clomipramine; Estrogen Replacement Therapy; Female; Hot Flashes; Humans; Meningeal | 1999 |
Citalopram: new indication. No advantage.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Clomipramine; | 1999 |
Sertraline in the treatment of anxiety disorders.
Topics: Adult; Clinical Trials as Topic; Clomipramine; Dose-Response Relationship, Drug; Drug Administration | 2000 |
Long-term effects of clomipramine and fluoxetine on dorsal periaqueductal grey-evoked innate defensive behaviours of the rat.
Topics: Aggression; Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Clo | 2001 |
The perils of fragmented sleep.
Topics: Adult; Clomipramine; Female; Humans; Nasal Obstruction; Panic Disorder; Sleep Wake Disorders | 1992 |
Painful ejaculation associated with antidepressants in four patients.
Topics: Adult; Antidepressive Agents, Tricyclic; Clomipramine; Depressive Disorder; Ejaculation; Humans; Imi | 1991 |
Higher postdexamethasone serum cortisol levels in agoraphobic than in nonagoraphobic panic disorder patients.
Topics: Adult; Agoraphobia; Clomipramine; Dexamethasone; Diagnosis, Differential; Female; Humans; Hydrocorti | 1991 |